Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person SARS‐CoV‐2‐related mortality · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Adverse events · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person All‐cause mortality · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Quality of life · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Hospitalisation · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Respiratory syncytial virus vaccine vs placebo Infant hospitalisation with clinically confirmed RSV disease · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Reduction in exposure to asbestos · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Asbestos concentration · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Asbestos concentration after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall CI: confidence interval. · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection CI: confidence interval. · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin A supplements vs placebo Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin A supplements vs placebo Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin A supplements vs placebo Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs placebo Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs paracetamol Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs placebo Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs placebo Serious adverse events (defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016)) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs paracetamol Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs paracetamol Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High sodium dialysate vs standard sodium dialysate Duration of hospital stay ‐ not reported · haemodialysis patients Interventions for preventing haemodialysis dysequilibrium syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Sodium modelling vs slow dialysis Duration of hospital stay ‐ not reported · haemodialysis patients Interventions for preventing haemodialysis dysequilibrium syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |